Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
NCT05985109 · Peking University Cancer Hospital & Institute · PHASE2 · terminated · last registry update 2026-11-03 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped early due to lack of efficacy.” | – | Registry record, Peking University Cancer Hospital & Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CTLA4 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-19Phase 3 first posted: Yao Hongwei, Ipilimumab & Sintilimab + Sintilimab (NCT07879599)
- 2026-10-19Phase 3 first posted: Yao Hongwei, Ipilimumab & Sintilimab + Sintilimab (NCT07879586)
- 2026-09-11Phase 3 first posted: Fudan University, Second-Line Chemotherapy + Cadonilimab (AK104) (NCT07815834)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Pembrolizumab/Quavonlimab (NCT04895722)
- 2026-02-17Phase 3 first posted: Akeso, Cadonilimab (AK104) + Oxaliplatin (NCT07412613)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision